Search results

 

Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
You searched for:
Results: 45
1

Respiratory diseases

Respiratory diseases   Chiesi Farmaceutici is fully committed to the care and improvement of the quality of life of people suffering from respiratory diseases including asthma and COPD (Chronic Obstructive Pulmonary Disease). Asthma and COPD are characterised by a reduction in the...
2

Neonatology

Normally, delivery takes place between the 37th and the 42nd week of gestation. By that time, the foetus is fully formed and developed enough to be able to adapt to extra-uterine life. However, in some cases delivery may occur before the 37th week of gestation. In that case, the neonate is...
3

Intensive care

Anaesthesiology, Algesiology and Intensive Medicine represent key areas of the company’s operation. A wide range of products was in-licenced for these specific areas of medicine.
4

Transplantation

Solid organ transplantation   A transplantation becomes necessary if an organ is no longer able to fulfil all of its functions. Today, this treatment method is a well-established, successful procedure, such that most patients can once again lead an almost normal life after the organ...
5

Jiné

-
6

Rare disease

-
7

Site Map

-
8

About us

Chiesi CZ s.r.o., is an affiliate of Chiesi Farmaceutici S.p.A. based in Parma, Italy - a multinational pharmaceutical company with more than 80 years of experience. Chiesi group focuses mainly on the research, development, production and marketing of innovative medicines...
9

Press release

-
10

Production plants

Chiesi Group has three production plants:   Parma, Italy. Blois-La Chaussée-Saint-Victor, France. Santana de Parnaíba, Brazil.   The plants produce in the whole more than 110 million units per year.   Italy     The production plant in Parma covers a total area of more than...
11

Cookies

-
12

Products

-
13

Search result

-
14

Therapeutic areas

-
15

Contacts

Chiesi CZ s.r.o.Smrčkova 2485/4 (DOCK IN TWO building)180 00 Praha 8, Česká Republika   Tel.: +420 261 221 745Fax: +420 261 221 767E-mail: chiesi-cz@chiesi.com   To report an adverse event and/or product defect E-mail: safety.cz@chiesi.comTel.: +420 730...
16

Management

-
17

GDPR

-
18

Code of Ethics

Guaranteeing the highest ethical standards at Chiesi is a priority which characterises every aspect of our day-to-day work. Our ethical principles are put into practice by affirming our values and protecting all areas involved in our activities. The society, the environment, and generally all those...
19

Transparency

-
20

Pharmacovigilance

Chiesi Farmaceutici has a system of pharmacovigilance in order to assume liability for our medicinal products (whether marketed or under clinical development) and to take appropriate actions when necessary. We ensure that all information relevant to the benefit-risk ratio of our medicinal products...
21

Credits

  This project was edited and produced by Dynamic Mind.
22

VPOIS

-
23

Chiesi is B corp

  Chiesi is the largest global pharmaceutical group to be awarded B Corp Certification, a recognition of high social and environmental standards. It’s an achievement to be proud of, and yet it feels natural: caring for others is at the root of health science and it has always been at...
24

History

-
25

Disclaimer

-
26

Annual report

-
27

Thomas Eichholtz appointed new Head of Global Research and Development at the Chiesi Group

-
28

Moderna and Chiesi Group Establish Collaboration to Discover and Develop mRNA Therapeutics for Pulmonary Arterial Hypertension (PAH).

CAMBRIDGE, Mass. and Parma, Italy   Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an international research-focused healthcare...
29

Lamzede®

Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.
30

Combair®

This fixed combination consists of an antiinflammatory inhalative corticosteroid and a long-acting bronchodilatory beta-2-sympathomimetic drug. Due to the synergism of both agents and its fast onset of action, it is indicated in the treatment of asthma bronchiale. Based on the Modulite®...
31

Peyona®

Peyona (caffeine citrate) is an orphan drug only for hospital use, registered by centralized procedure and indicated for the treatment of primary apnoea of premature newborns. This pathology is characterised by the incomplete development of the brain centres which control the respiration. The...
32

Otobacid N

This combination contains dexamethasone, an anti-inflammatory glucocorticoid, dibucaine (cinchocaine), a local anaesthetic and long-acting chinoline derivative, and butanediole, a polyvalent alcohol with antiseptic properties. It is used in the therapy of inflammatory diseases of the ear...
33

Fentanyl Torrex

Fentanyl, a powerful narcotic analgesic, is used as an analgetic component for general anaesthesia. It is approximately 100 times more potent than morphine and a very fast acting substance.
34

Atimos®

Formoterol is an inhalative long-acting beta-2-agonist which acts as a bronchodilator. It is indicated in patients with obstructive pulmonary disease.
35

Flamexin®

Piroxicam betadex is a non-steroidal anti-inflammatory drug (NSAID) which acts as an antiphlogistic, analgesic and antipyretic. In comparison to pure piroxicam, this agent has a faster onset of action and better gastrointestinal tolerance. It is used to relieve painful conditions such as...
36

Sufentanil Torrex

Sufentanil is a synthetic opioid analgesic drug which is seven to ten times more potent than Fentanyl. It is used either as analgesic component or as an anaesthetic agent for the induction and maintenance of balanced anaesthesia.
37

Envarsus®

Envarsus® is a once daily prolonged-release tablet containing tacrolimus monohydrate. The product is indicated for the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and for treatment of allograft rejection resistant to treatment with other immunosuppressive...
38

Bramitob®

Tobramycin is an aminoglycoside antibiotic which is produced by Streptomyces tenebrarius and it is administered via inhalative route. The therapeutic indication is the management of chronic pulmonary infections caused by pseudomonas aeruginosa in patients with cystic fibrosis.
39

Curosurf®

Our product is a natural surfactant for substituting a lack of endogenous surfactant and is administered via intratracheal instillation. It adheres to the alveoli and reduces the surface tension, thereby preventing atelectasis (ventilation deficiency in the lung). The insufficiency of surfactant...
40

Quinsair®

-
41

Trimbow®

-
42

Procysbi®

-
43

Kengrexal®

-
44

Budiair®

Budesonide is used as an inhalative glucocorticoid in the treatment of asthma bronchiale and chronic obstructive bronchitis. Modulite® technology enables optimized particle-size and, as a result, better lung deposition and a pronounced anti-inflammatory effect. We offer the product with and...
45

Combair NEXThaler®

-